2026年10月16日星期五
M
Weltübersicht
Globale Kurznachrichten
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Global pharma firms walk back innovative drug investments in Japan

Quelle 日经 Nikkei AsiaVor 2 Stunden
Inhaltszusammenfassung

Global pharma firms walk back innovative drug investments in Japan

Diese Website bietet nur Titel- und Zusammenfassungsindexe. Der vollständige Inhalt und das Urheberrecht liegen beim ursprünglichen Herausgeber. Bitte klicken Sie auf den Original-Link, um ihn zu lesen.

Zum Originaltext
Zugehöriger Kanal
Wirtschaft und Finanzen
Zugehörige Region
Japan
Originalsprache
English
Eintragsnummer
business-839627c8

Comments 0 comments

No comments yet. Be the first.

Global pharma firms walk back innovative drug investments in Japan · Weltübersicht